查詢結果分析
來源資料
相關文獻
- 磷酸比哆醛抑制血小板凝集作用與血小板形態變化之探討
- 厭氧流體化床之生物膜顆粒層次模型及代謝活性試驗
- 鋼鋁片鍍層與化成塗膜表面分析技術之應用
- Cytokines and Growth Factors Secreted by Vero Cells Destined for Embryo Cocultures
- Comparison of Upper Floret Development in Bisexual and Male Spikelets of Thuarea Involuta (Gramineae) with Scanning Electron Microscopy
- 新生兒異族免疫性血小板低下症
- Different Densities of Human Eosinophils Respond Differently to PAF and IL-5
- Idiopathic Thrombocytopenic Purpura Preceding Malignant Lymphoma: Report of One Case
- Synthesis and Antiplatelet Activity of 5-Methyl-2-Furyl Methyl Ketone Phenylhydrazones and Related Compounds
- Synthesis and Antiplatelet Activity of 1,3-Disubstituted 5-Methylthieno[3,2-c]Pyrazoles
頁籤選單縮合
題 名 | 磷酸比哆醛抑制血小板凝集作用與血小板形態變化之探討=Anti-Aggregative Effects of Pyridoxal-5'-Phosphate on Platelet Morphological Changes |
---|---|
作 者 | 尤文正; 戴儒君; 張素瓊; | 書刊名 | 臺灣營養學會雜誌 |
卷 期 | 35:3 2010.09[民99.09] |
頁 次 | 頁98-108 |
分類號 | 346.76 |
關鍵詞 | 磷酸比哆醛; 血小板; 掃描式電子顯微鏡; Pyridoxal-5'-phosphate; PLP; Platelets; Canning electronic microscopy; SEM; |
語 文 | 中文(Chinese) |
中文摘要 | 磷酸比哆醛(Pyridoxal-5'-phosphate, PLP)是維生素B6存在於體內的主要活化形式,本研究室先前研究顯示,PLP具有抑制血小板凝集與血液凝固的功能,可能有益於預防心血管疾病。然而,其作用機制與對血小板形態之影響則尚未闡明。本研究利用thrombin,ADP,與collagen等血小板致凝劑誘導富含血小板血漿(platelet rich plasma, PRP)產生凝集現象,使用掃描式電子顯微鏡(SEM)觀察血小板形態變化,並對照可專一性結合表面蛋白GPllb-llla (GP23)的四胜肽血小板凝集抑制劑(Arg-Gly-Asp-Ser, RGDS)的作用,探討PLP對這些致凝劑所誘發的血小板凝集作用的可能機制。結果顯示,thrombin,ADP,collagen對血小板之最強致凝濃度分別為0.5 units/mL,25 μM,0.1 mg/mL。PLP及RGDS對三種致凝物之最強抗凝濃度均分別為1.5 mM與0.23 mM。電子顯微鏡觀察的結果發現,以PLP或RGDS預處理的血小板與致凝物反應後,血小板外觀的變化類似,包括血小板變形現象減少,維持在偽足伸出形態,及較少的凝血蛋白束等。此外,使用thrombin作為致凝物時,以PLP或RGDS處理後的血漿凝血蛋白束均變小,這可能是PLP與RGDS延長血液凝固時間的原因之一。本研究結果顯示PLP可能部分透過與RGDS勝肽抑制血小板凝集的途徑,減少GP23與Fb的結合以抑制血小板凝集。 |
英文摘要 | Pyridoxal-5'-phosphate (PLP), the active form of vitamin B6, was previously studied in our laboratory as a potential anti-aggregative agent which has beneficial effects in preventing cardiovascular diseases. However, the relationship between the anti-aggregative effects and morphological changes of PLP is unclear. In this study, platelet-rich plasma (PRP) was respectively activated by thrombin, ADP, end collagen and co-incubated with the tetrapeptide, Arg-Gly-Asp-Ser (RGDS), or PLP. Morphological changes in platelets were evaluated by scanning electronic microscopy (SEM). The results indicated that optimal aggregative concentrations of thrombin, ADP, and collagen were 0.5 units/mL, 25 μM, and 0.1 mg/mL, respectively. Meanwhile, the optimal anti-aggregative concentrations of PLP and RGDS to those platelet agonists were 1.5 and 0.23 mM, respectively. The SEM data showed that morphological changes in platelet by RGDS or PLP treatment were similar, including lower activation, being sustained in the pseudopod stages, and having smaller fibrin spindles during thrombin induction. The smaller fibrin spindle formation caused by PLP or RGDS might be helpful in preventing blood coagulation. In this study, we provide morphological evidence that the anti-aggregative effect of PLP is partially similar to that of RGDS in inhibiting fibrinogen binding to GP23 receptors. |
本系統中英文摘要資訊取自各篇刊載內容。